XJN010
/ Guangzhou Novaken Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2025
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
(clinicaltrials.gov)
- P2 | N=84 | Recruiting | Sponsor: Guangzhou Novaken Pharm Co., Ltd.
New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1